Search This Blog

Monday, December 2, 2019

Lexicon loses appeal of sotagliflozin CRL; shares down 10% premarket

The FDA has denied Lexicon Pharmaceuticals’ (NASDAQ:LXRX) appeal of the CRL it received in March related to its marketing application for type 1 diabetes med sotagliflozin. Undeterred, it now plans to appeal the decision to the Center for Drug Evaluation and Research (CDER).
The company will host a conference call this morning at 8:00 am ET to discuss the matter.
Shares down 10% premarket on light volume.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.